Wei‐Hong Zhang
Papers
1
Total Citations
62
H-Index
1
About
Wei-Hong Zhang is a leading clinical researcher in thoracic oncology, with a primary focus on esophageal squamous cell carcinoma (ESCC) and multimodal treatment strategies. His most impactful work centers on neoadjuvant chemoimmunotherapy, particularly the combination of pembrolizumab with paclitaxel and cisplatin for locally advanced resectable ESCC. His landmark study, the Keystone-001 phase-II trial protocol (62 citations), addresses a critical gap in treatment for stage III disease, where over 50% of global EC cases occur in China. Zhang’s contributions have helped shape perioperative management paradigms, demonstrating how immunotherapy can be safely integrated before surgery to improve resectability and outcomes. By designing rigorous, prospective single-arm trials, he provides high-quality evidence for NCCN-aligned protocols in high-burden populations. His work is widely cited for its translational relevance, bridging immunotherapy advances with real-world surgical oncology. Zhang’s research continues to influence clinical guidelines and offers a promising pathway for patients with refractory ESCC, positioning him as a key figure in the evolution of neoadjuvant treatment for thoracic malignancies.
Research Focus
Key Achievements
Top Papers
- 1